Erlotinib As Single Agent First Line Treatment in Locally Advanced or Metastatic Activating EGFR Mutation-Positive Lung Adenocarcinoma (CEETAC): an Open-Label, Non-Randomized, Multicenter, Phase IV Clinical Trial